StockData
Globus Medical Inc logo

Globus Medical Inc (GMED) company profile

GMEDNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 22/3044% below fair value
$70.53+0.54 (+0.77%)

Close on Nov 18, 2026Market cap $9.47BP/E 18.0Yield –

About Globus Medical

Surgical & Medical Instruments & Apparatus, SIC 3841

Globus Medical, Inc. develops and commercializes healthcare solutions designed to treat musculoskeletal disorders and improve patient quality of life. The company operates through two primary product categories: Musculoskeletal Solutions and Enabling Technologies. Its offerings include spinal implants, motion preservation devices, regenerative biologics, orthopedic trauma hardware, joint replacement systems, and spinal cord stimulation therapies for chronic pain management. Globus also provides intraoperative neuromonitoring services and advanced surgical systems comprising robotic guidance, imaging platforms, navigation headsets, and surgical planning software. The company primarily serves surgeons, physicians, ambulatory surgery centers, and hospitals.

Headquartered in Audubon, Pennsylvania, Globus distributes its technologies across 65 countries worldwide, operating in the United States and 64 international territories. The company maintains in-house implant manufacturing facilities in Eagleville and Limerick, Pennsylvania, as well as West Carrollton, Ohio. Biologics processing is conducted in Audubon, Pennsylvania, and San Antonio, Texas. In addition, Globus manufactures spinal cord stimulation products in Costa Rica and assembles its robotic surgical platforms in Methuen, Massachusetts.

Summary of the business section of Globus Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
Globus Medical Inc
Founded
2003
Headquarters
Audubon, PA
Address
2560 General Armistead Avenue 19403
Phone
(610) 930-1800
Employees
6,000, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
DELOITTE & TOUCHE LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
GMED
Exchange
NYSE
IPO date
Aug 3, 2012
Shares outstanding
134M, Aug 4, 2026
Public float
$6.60B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1237831
CUSIP
379577208
ISIN
US3795772082
FIGI
BBG002V87SD0
Share class FIGI
BBG002V87T57
LEI
5299003M2P4CIK0RF205
EIN
04-3744954

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
David C. PaulExecutive Chairman, Director23,087,808
Keith W. PfeilPresident, CEO, Director5,833
Daniel T. ScavillaPresident, CEO, Director0
Kelly HullerEVP, GC, Corporate Secretary0
Kyle KlineSenior Vice President, CFO0
James R. TobinDirector0
Ann D. RhoadsDirector35,384
Stephen T. ZarrilliDirector25,000
David D. DavidarDirector673,642
Robert Andrew DouglasDirector2,005
Leslie V. NorwalkDirector10,419
Dan WoltermanDirector24,025
John A. DeFordDirector15,578
Dan LemaitreDirector1,097

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Daniel T.Scavilla
$5.32M-$5.70M$2.66M$134$127
FY2025
Keith W.Pfeil
$4.40M$4.96M$2.66M$134$127
FY2024
Daniel Scavilla
$4.86M$9.50M$2.35M$127$117
FY2024
Daniel T.Scavilla
$4.86M$9.50M$2.35M$127$117
FY2023
Daniel Scavilla
$4.56M$1.88M$2.31M$82$106
FY2023
Daniel T.Scavilla
$4.56M$1.88M$2.31M$82$106

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
David C. Paul
Chairman of the Board of Directors and Executive Chairman
$469.39K$100.00K$2.68M$1.02M$34.68K$4.31M+41%
Keith W. Pfeil
Chief Executive Officer and President
$479.47K$117.00K$2.98M$783.00K$38.35K$4.40M+86%
Kyle R Kline
Senior Vice President and Chief Financial Officer
$334.04K$50.00K$762.95K$200.00K$33.26K$1.38M–
Kelly G. Huller
Executive Vice President, General Counsel and Corporate Secretary
$364.08K$40.00K$1.43M$411.71K$34.58K$2.28M+40%
Daniel T. Scavilla
Former Chief Executive Officer and President
$284.62K–$5.01M–$25.68K$5.32M+9%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 3, 2012
Offer price
$12.00
Securities offered
8,333,333
Gross proceeds
$100.00M
Exchange
NYSE
First trading day
Aug 3, 2012
First-day close
$13.50+12.5%
Lock-up ends (est.)
Jan 30, 2013

“The initial public offering price is $12.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had over 6,000 employees worldwide, including sales and marketing, product development, operations, general administrative and accounting, both domestically and internationally.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?